Sorafenib for the treatment of unresectable hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37368694

about

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New Hepatocellular carcinoma: Where are we?Targeting angiogenesis in gynecologic cancers Role of microRNAs in hepatocellular carcinoma: a clinical perspective Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells New inhibitors of VEGFR-2 targeting the extracellular domain dimerization process.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study.A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.Advances in paediatric cancer treatment Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management Knockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells.Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma.Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis.Targeting integrins in hepatocellular carcinoma.Recent advances in anti-angiogenic therapy of cancer Role of stress-induced NKG2D ligands in liver diseases.Current concepts in pediatric liver tumors.

P2860

Q26744542-7B258D7E-5EA4-42A9-86AE-20699EA4A412 Q26765182-C6BC6DE1-E91D-47E1-B98E-493479D34C29 Q26824766-05316786-2C00-4A81-8E95-B0BF5674EDE4 Q27014034-F556955A-0B84-4891-A88B-BFCC0A29B95C Q28079378-DDA9953E-7FD5-4427-B1F7-58CE3F933F5A Q28477884-89FCEEEE-3583-48CF-8719-2C3D541EB185 Q28539940-3CE2CFAB-6593-4EA4-ACEF-E4F41E265A35 Q34027266-77A82197-58AC-4593-B932-19B50CC9FC16 Q34131801-4FF1A5D1-BF3E-448F-B0BA-FCC1491E9EC1 Q34229404-5DCB7019-02CA-414F-AF71-D2C7A80BB4D2 Q34402062-20B6E598-7D52-4A23-BE0E-7D4C6C38677B Q34675280-24B3503A-97D9-460F-81CB-BE87075E5BC8 Q34758477-12624023-633D-4ACC-97D9-164D7F55932F Q35005616-B72BEAB9-4E6C-41D0-89F3-4261202A237C Q35030418-C3CD1DB9-A791-49B9-92BF-33F073EF4B29 Q35205410-D3A9B0FD-B794-4638-A2EA-50EF96606710 Q35626761-7F628984-43D2-4445-ADAF-6325724172F2 Q35740123-454C54B6-C705-4CE3-9D40-470174C172EB Q35759606-8120734F-04AE-41D7-8068-77B7D8105EC3 Q35963024-2A8D74EC-A006-4CC4-A2DB-E500EB757E74 Q36224737-694A6159-7DE3-4036-B423-CDFD1D2D98F1 Q36508630-D5A19A24-6B47-45FA-B89F-9F65DCC2420F Q36654402-E8C0C519-70A5-4E99-95FF-8903CE81FFD6 Q36922232-9EFBB636-E86F-4208-BC5E-772E46926B25 Q37017008-6E6447D6-28E1-4B49-899D-D8EF12875CF5 Q37046852-A5BBB18E-629D-4FC9-9F5B-8DFDD9399063 Q37138893-CE5A798A-0CF9-4974-85ED-27C6E898394A Q37317462-85DA5F4C-4DC7-4403-AD94-869F872D2E22 Q37441525-61102DAB-5610-4F52-B7D2-0F3A0E53B6C6 Q37595952-D4CB6F9F-B09A-47BC-977F-54066E870B73 Q37621007-615E7B37-4043-4327-A862-1B06D22B615A Q37687133-8741FEB6-E340-4E44-9A9E-117E9FAF75A6 Q37719254-DB70016D-0191-4D60-BCAD-97D8A56624FB Q37766533-977F37BD-D408-4BCD-A80A-3CC65F03B7E7 Q37827878-E3CD0649-2CC2-4FEE-8AA7-D958B0F7800B Q37828119-7A6DD1C5-391D-4328-8BC6-D8E589651474 Q37844564-CC67A5C7-760F-4568-AC57-A1221CB57560 Q37852512-B8F17B80-7B66-42E3-AD64-CE214B3BE118 Q37957971-79A1A30A-960D-4D24-9874-E933FDED0342 Q38007187-858247F5-EF9C-41CC-AA0B-5110079B8AA5

P2860

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37368694

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

@en

type

label

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

@en

prefLabel

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

@en

P1433

Q37368694-ABF00926-0B82-45F6-83C2-E41F8B084489

P1476

Q37368694-8ACDCB60-4A7A-4600-8386-6E7D5AEE26A8

P2093

Q37368694-232D4E8D-787F-4DED-8EBB-F0B260F4DDFC

Q37368694-3CF2428E-1B30-40EB-BA61-8CBBE88FA041

Q37368694-4DE9D62B-7E14-4DBB-91CF-08FCA7933371

Q37368694-67AD587C-271E-44B5-ABA3-D5A0D1DBFCA7

Q37368694-81B06E1C-4797-4FFA-991A-61B9010A71B5

Q37368694-84AFD6E4-96EE-4C68-9CD3-FE5FC29B7A59

Q37368694-86805D69-A15D-4232-9106-8B9F1FF774A8

Q37368694-F65F610B-2759-474A-A9DE-D9A2F8968C3E

P304

Q37368694-1295B7F4-938D-46FE-85BB-60B973D65AEB

P31

Q37368694-90449736-D7AB-4FB7-B642-C20E5769A96C

P356

Q37368694-6F12A96F-ED40-4596-AF2A-97BD61015CEB

P433

Q37368694-5D6B3C62-79E8-49F9-B4E6-046EFD6B2777

P478

Q37368694-A7CFDF38-C5CE-4525-A7A3-0E09FDB75473

P577

Q37368694-410CA88C-B8D2-4D02-A7A2-7B4495DC5EFA

P698

Q37368694-3C73E96E-6133-45E0-B80A-FFB68C0C1A59

P356

THEONCOLOGIST.2008-0185

P1433

P1476

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

@en

P2093

Ann T Farrell

http://www.w3.org/2001/XMLSchema#string

Brian Booth

http://www.w3.org/2001/XMLSchema#string

Rajanikanth Madabushi

http://www.w3.org/2001/XMLSchema#string

Rajeshwari Sridhara

http://www.w3.org/2001/XMLSchema#string

Richard Pazdur

http://www.w3.org/2001/XMLSchema#string

Robert C Kane

http://www.w3.org/2001/XMLSchema#string

Robert Justice

http://www.w3.org/2001/XMLSchema#string

Somesh Chattopadhyay

http://www.w3.org/2001/XMLSchema#string

P304

95-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2008-0185

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19144678

http://www.w3.org/2001/XMLSchema#string